Blog
RSS FeedPosted by Michael Wonder on 08 May 2020
HyQvia gets a higher price
8 May 2020 - HyQvia 100 mg/mL solution for injection contains human immunoglobulin, which is an antibody used to strengthen ...
Posted by Michael Wonder on 30 Apr 2020
Health economic assessment of Keytruda in head and neck cancer
29 April 2020 - TLV has developed a health economic knowledge base for the regions of the drug Keytruda (pembrolizumab). ...
Posted by Michael Wonder on 20 Apr 2020
Epidyolex is granted temporary subsidy
20 April 2020 - The TLV has decided that Epidyolex 100 mg /mL oral solution should be included in the ...
Posted by Michael Wonder on 20 Apr 2020
Additional analysis of Kymriah in the treatment of patients with diffuse large-cell B-cell lymphoma
17 April 2020 - TLV has conducted an additional analysis of the earlier evaluation of Kymriah (tisagenleclucel) in the treatment ...
Posted by Michael Wonder on 03 Apr 2020
The review shows that it is possible to lower the cost of medicines
3 April 2020 - There are opportunities to make savings on medicines. ...
Posted by Michael Wonder on 02 Apr 2020
Pharmacies may only dispense drugs for 90 days
1 April 2020 - As of today, April 1, pharmacies cannot deliver a larger amount of drug than the amount ...
Posted by Michael Wonder on 31 Mar 2020
Health economic assessment of Keytruda in combination with Inlyta in kidney cell cancer
31 March 2020 - TLV has developed a health economic knowledge base for the regions for combination treatment with the drugs ...
Posted by Michael Wonder on 23 Mar 2020
COVID-19 and processing times
23 March 2020 - At present, TLV's operations continue as usual. ...
Posted by Michael Wonder on 17 Mar 2020
Erlotinib new exchange groups
13 March 2020 - As of April, erlotinib is included as an exchange group on the list of goods for ...
Posted by Michael Wonder on 16 Mar 2020
TLV has decided to reconsider subsidy restrictions for several drugs
16 March 2020 - TLV starts two different re-examination of subsidy restrictions for certain drugs and drug groups with the ...
Posted by Michael Wonder on 09 Mar 2020
Health economic assessment of Kadcyla in the treatment of HER2 positive, early breast cancer
6 March 2020 - TLV has developed a health economic knowledge base for the regions for the drug Kadcyla (trastuzumab emtansine). ...
Posted by Michael Wonder on 25 Feb 2020
TLV has decided on a policy for patient participation
21 February 2020 - TLV has taken another step in developing patient participation by developing a policy. ...
Posted by Michael Wonder on 16 Feb 2020
New and removed exchange groups
14 February 2020 - An exchange group is a group of drugs that the Swedish Medicines Agency has judged to be ...
Posted by Michael Wonder on 12 Feb 2020
Withdrawal from the drug benefits on 1 March 2020
12 February 2020 - Aprovel, Differin and Plavix are among the medicines that are withdrawn from the drug benefits at the ...
Posted by Michael Wonder on 05 Feb 2020
Mayzent is granted temporary subsidy
5 February 2020 - The Dental and Pharmaceutical Benefits Agency has decided that Mayzent, 0.25 and 2 mg film-coated tablet ...